Best Cell Therapy Companies in California, United States

Orca Bio is a developer of Allogeneic cell therapy for cancer, autoimmune diseases and genetic blood disorders. It uses OrcaSort technology that is an enabling feature for the scalability and high-precision of the manufacturing platform. It also helps in the isolation and purification of stem cells and immune cells used in hematopoietic cell grafts. The components of the technology are optimized for performance and designed to fit seamlessly into the clinical processing of apheresis products. It has developed therapeutic solutions for regulatory T cells that aims to temper the immune reaction. It reduces the fatal complications and provides maximum control of the development of the patient's new immune system.

Funding rounds

• Jan 2026Series F$250M
• Nov 2019Series D$192M

Founders & team

Jeroen BekaertCo-Founder & COOIvan DimovCo-Founder & Co-CEO

Investors

Lightspeed Venture Partners, 8VC, DCVC, ND Capital, IMRF, Kaiser Permanente

Tech stack

Amazon Web ServicesApple Icloud MailBackbone.JsBrizy WordpressBunnyBunny Fonts

Provider of genomic-based personalized pluripotent stem cell therapy. It offers regenerative cell treatment like dopaminergic neurons for Parkinson's disease and other neurological disorders. It maintains the genetic-based quality control to avoid the mutation of cells used for therapy.

Funding rounds

• Nov 2025Series C$115M
• Dec 2022Conventional Debt$40M
• May 2022Series B$147.5M
• Apr 2020Series A$70M

Founders & team

Damien McdevittPresident

Investors

Orbimed, Arch Venture Partners, Frazier Healthcare Partners, Domain Associates, S32, Google Ventures

Tech stack

CloudflareCloudflare Bot ManagementCore-JsGeneratepressGeneratepress Gp PremiumGodaddy

Developer of CAR- T therapy for cancer treatment. The lead CAR program LYL797is developed for the treatment of ROR1+ non-small cell lung cancer and triple-negative breast cancer. Another candidate LYL845 is an autologous TIL therapy for the treatment of multiple solid tumors.

Funding rounds

• Jul 2025Post IPO$100M
• Mar 2020Series C$493M
• 2018Seed—

Founders & team

Stan RiddellCo-FounderCrystal MackallCo-FounderRick KlausnerCo-Founder

Investors

GSK, Sahsen Ventures, 8VC, Foresite Capital, Arch Venture Partners, Mubadala

Tech stack

Amazon Web ServicesBootstrapCloudflareCloudflare Bot ManagementFont AwesomeGoogle Analytics

Developer of CAR-T cell therapies for the treatment of cancer

Developer of cell-based therapies to treat intractable neurological diseases. It generate therapeutic compositions of a specific type of nerve cell (or neuron) for targeted delivery into the injured nervous system. It offers NRTX-1001, an inhibitory neuron therapy for epilepsy by GABAergic inhibition, reduce seizure activity, and repair the affected neural network.

Funding rounds

• Mar 2025Series E$102M
• Feb 2024Series E$120M
• Dec 2022Series D$72M
• Jun 2021Series C$41.5M

Founders & team

Cory NicholasCEO

Investors

UCB Ventures, Ironfire Ventures, Alexandria, Sphera Fund, The Column Group, Viking Global Investors

Tech stack

Apache Http ServerApple Icloud MailCookieyesGoogle AnalyticsGoogle Hosted LibrariesHsts

Developer of regenerative and gene therapeutics for heart failure. The company's pipeline include MYBPC3 for genetic hypertrophic cardiomyopathy, PKP2 for genetic arrhythmogenic right ventricular cardiomyopathy, DWORF for dilated cardiomyopathy, and HDAV6i for heart failure with preserved ejection fraction.

Funding rounds

• Feb 2025Grant (prize money)$8M
• Mar 2021Series C$106M
• Oct 2019Series B$92M
• Dec 2016Series A$50M

Founders & team

Benoit BruneauCo-FounderBruce ConklinCo-Founder

Investors

RTW Investments, RA Capital Management, Fidelity Investments, The Column Group, Casdin Capital, Google Ventures

Tech stack

Acquia Cloud PlatformAcquia Cloud Site FactoryAkamaiAmazon Web ServicesBackbone.JsBootstrap

Developer of immune cell therapies for cancer treatment. It develops programmable immune cell therapies using cloud computing, genome engineering, and synthetic immunology technologies. It offers a pipeline of drug candidates which include AB-2100 for kidney cancer, and AB-3000 targeted at prostate cancer.

Funding rounds

• Jul 2024Series C$325.4M
• Sep 2022Series B$220.8M
• Oct 2019Series A$85M

Founders & team

Ken DrazanCo-Founder & CEO

Investors

Bristol-Myers Squibb, Westlake Village Biopartners, SoftBank Vision Fund, Byers Capital, Emerson Collective, Green Sands Equity

Tech stack

Amazon S3Amazon Web ServicesApple Icloud MailAxiosCookieyesCore-Js

Developer of cell therapy products for blood cancers, tissue damage healing & radiation poisoning. The lead product, HPC, Marrow is a cell therapy product derived from HLA-matched hematopoietic progenitor cell (HPC) of bone marrow. These cells can be used for hematopoietic reconstitution for patients suffering from blood cancers including leukemia. Other products under development are CHIMERA is for improving organ transplantation and CHYMALIS is a cell therapy derived from mesenchymal stem cells (MSCs) from bone marrow for tissue damage healing & radiation poisoning. The company also provides bone marrow (BM) cells for labs doing research in oncology, immunology, etc.

Funding rounds

• Aug 2024Grant (prize money)$375.1K
• Jul 2023Series C$52M
• Apr 2023Grant (prize money)$3.5M
• Sep 2021Grant (prize money)$361.6K

Founders & team

Kevin CaldwellCo-Founder & CEOErik WoodsCo Founder

Investors

General Catalyst, Vivo Capital, First Round Capital, XYZ Venture Capital, Manta Ray Ventures, CPMG

Tech stack

All In One SeoCloudflareCloudflare Browser InsightsCloudflare Rocket LoaderCore-JsGoogle Analytics

Developer of chimeric antigen receptor cell therapy to treat cancer. The lead candidate of the company ALLO-501A targets CD-19 in refractory non-Hodgkin lymphoma. Other drug candidates include ALLO-316 and ALLO-647 for hematological malignancies and solid tumors.

Funding rounds

• Apr 2024Grant (prize money)$15M
• Sep 2018Series A$120M
• Jun 2018Grant (prize money)$58.3K
• Apr 2018Series A$411.8M

Founders & team

David ChangPresident and Chief Executive Officer

Investors

Europa, Vida Ventures, Pfizer, TPG, Bellco Capital, CIRM

Tech stack

Acquia Cloud PlatformAcquia Cloud Site FactoryAdobe AnalyticsAdobe Experience Platform Identity ServiceAdobe Experience Platform LaunchAmazon Web Services

Developer of T-cell therapeutics for cancer treatment. The company's lead product candidate BAFF-R CAR-T was constructed which is found to kill lymphomas and leukemias in-vitro as well as established lymphoma in vivo. The product is under IND enabling study for its further development.

Developer of cell therapies for age-related and disease-related immune deficits. It offers a STEM product line developed from human stem cells that secrete immune modulators for treating muscle atrophy in patients with knee osteoarthritis and muscle performance in seniors with obesity and muscle weakness.

Angiocrine Bioscience develops therapeutics based on genetically modified endothelial cells. Their proprietary E-CEL Technology comprises cultured endothelial cells that have been genetically modified via insertion of the adenovirus E4ORF1 gene. This allows the cells to grow ex-vivo and secrete angiocrines that promote tissue regeneration. The company is currently investigating applications in lung regeneration, sports medicine and immune regeneration in indications such as high-risk hematological malignancies and sickle cell anemia.